Donald E. Bobo, Jr. Sells 5,500 Shares of Edwards Lifesciences Corp (EW) Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,500 shares of Edwards Lifesciences stock in a transaction on Wednesday, October 10th. The stock was sold at an average price of $147.50, for a total transaction of $811,250.00. Following the completion of the transaction, the vice president now directly owns 25,490 shares in the company, valued at $3,759,775. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of Edwards Lifesciences stock opened at $143.39 on Friday. The company has a current ratio of 1.86, a quick ratio of 1.47 and a debt-to-equity ratio of 0.19. The firm has a market cap of $36.45 billion, a price-to-earnings ratio of 37.73, a P/E/G ratio of 2.41 and a beta of 0.56. Edwards Lifesciences Corp has a 12-month low of $100.20 and a 12-month high of $175.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, July 26th. The medical research company reported $1.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.11. The business had revenue of $972.00 million for the quarter, compared to the consensus estimate of $968.32 million. Edwards Lifesciences had a net margin of 19.59% and a return on equity of 29.11%. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.08 EPS. On average, analysts forecast that Edwards Lifesciences Corp will post 4.67 earnings per share for the current year.

Several research analysts recently commented on EW shares. BMO Capital Markets lifted their target price on shares of Edwards Lifesciences to $162.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 10th. Northland Securities reaffirmed a “hold” rating and issued a $120.00 target price on shares of Edwards Lifesciences in a research note on Thursday. Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Wednesday, September 26th. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $133.00 to $150.00 and gave the company a “neutral” rating in a research report on Friday, July 27th. Finally, ValuEngine downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, August 8th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $155.30.

Several large investors have recently added to or reduced their stakes in EW. Commonwealth Equity Services LLC grew its position in shares of Edwards Lifesciences by 11.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 26,399 shares of the medical research company’s stock worth $3,683,000 after buying an additional 2,816 shares during the period. Lord Abbett & CO. LLC grew its position in shares of Edwards Lifesciences by 32.4% in the 1st quarter. Lord Abbett & CO. LLC now owns 113,065 shares of the medical research company’s stock worth $15,775,000 after buying an additional 27,667 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of Edwards Lifesciences by 5.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 234,093 shares of the medical research company’s stock worth $32,661,000 after buying an additional 11,344 shares during the period. United Capital Financial Advisers LLC grew its position in shares of Edwards Lifesciences by 185.9% in the 1st quarter. United Capital Financial Advisers LLC now owns 24,001 shares of the medical research company’s stock worth $3,349,000 after buying an additional 15,607 shares during the period. Finally, Natixis grew its position in shares of Edwards Lifesciences by 138.3% in the 1st quarter. Natixis now owns 37,446 shares of the medical research company’s stock worth $5,224,000 after buying an additional 21,733 shares during the period. 82.10% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Featured Story: Understanding Analyst Ratings

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply